Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080125 | 0.88 | CYP3A4 (0.35) | MAPTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL14064602 | 0.87 | KDM4E (0.38) | MAPTALDH1A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL2079609 | 0.85 | GAA (0.38) | ALDH1A1MEN1KMT2AGAA | |
| SCHEMBL1170226 | 0.85 | LMNA (0.36) | MAPTALDH1A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL12864836 | 0.85 | LMNA (0.36) | MAPTALDH1A1KDM4EMEN1ALOX15 | |
| SCHEMBL2079178 | 0.84 | ALDH1A1 (0.34) | MAPTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2080920 | 0.84 | ALDH1A1 (0.39) | MAPTALDH1A1CYP3A4CYP2C19MEN1 | |
| SCHEMBL1169665 | 0.82 | KDM4E (0.34) | MAPTALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1169995 | 0.79 | LMNA (0.35) | MAPTALDH1A1CYP2C9CYP2C19KDM4E | |
| SCHEMBL2080717 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-7897593-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| WO-2007143446-A1 | SPIRO-CONDENSED HETEROTRICYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
| US-20070281917-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281917-A1 | HIV Integrase Inhibitors | TYMP, POLN, IMPDH1 | MAPT 3231/4885ALDH1A1 301/4885CYP3A4 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.